47c0b7df-a564-4e71-8d90-ba07bac40f59
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- PROTEIN_SECRETION+0.500
- ANDROGEN_RESPONSE+0.400
- G2M_CHECKPOINT+0.400
- MYC_TARGETS_V1+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- HEDGEHOG_SIGNALING+0.300
- MITOTIC_SPINDLE+0.300
- MTORC1_SIGNALING+0.300
- MYC_TARGETS_V2+0.300
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.300
- KRAS_SIGNALING_DN-0.300
- IL6_JAK_STAT3_SIGNALING-0.200
- INTERFERON_GAMMA_RESPONSE-0.200
- P53_PATHWAY-0.200
- ALLOGRAFT_REJECTION-0.100
- BILE_ACID_METABOLISM-0.100
- KRAS_SIGNALING_UP-0.100
- OXIDATIVE_PHOSPHORYLATION-0.100
- PANCREAS_BETA_CELLS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG308 | — | — | 0.842 |
| 2 | 2723b191-7c84-4edd-b0d0-da8ba4a1a894 | — | — | 0.821 |
| 3 | TCGA-BT-A20U-01A-11R-A14Y-07 | — | — | 0.811 |
| 4 | BDEB76B7-B7E0-4058-82A2-77E93748C936 | — | — | 0.803 |
| 5 | 8E898165-F557-4D73-9D67-ED735BE256B2 | — | — | 0.802 |
| 6 | TCGA-85-7844-01A-11R-2125-07 | — | cohortSQ2 | 0.801 |
| 7 | B7B9B5C1-C11D-47B8-B2F8-A5660AB961C1 | — | — | 0.799 |
| 8 | MDT-AP-3249 | Med | Medulloblastoma | 0.788 |
| 9 | SJEPD031429_D1.RNA-Seq | EPN | EPN Tumor | 0.784 |
| 10 | SRR9879279 | — | cohortA1 | 0.779 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.500 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |